Molecular Partners AG (SIX: MOLN, Nasdaq: MOLN)

https://www.molecularpartners.com

Molecular Partners is a privately-owned biotech company focusing on the research, development and commercialization of a novel class of biological drugs known as DARPins®. The company is committed to create medicines for diseases with unmet medical need and to dramatically improve existing therapies. DARPins® combine the high specificity, selectivity and safety of monoclonal antibodies with many advantages of small molecules, including high stability and low-cost production and adding the ability of combining multiple specificities. Molecular Partners has established a strong DARPin® pipeline which is well differentiated from standard therapeutic approaches. Molecular Partners is focusing on DARPin® drugs in inflammation, oncology, ophthalmology and other disease areas. The most advanced DARPin (MP0112/ AGN 150998) is in phase IIb clinical development and has been partnered with Allergan. The internal pipeline is expanded by partnered programs with leading pharmaceutical companies. Molecular Partners has established collaborations with Allergan, Janssen Biotech and others. The company is backed by a strong syndicate of investors and holds a strong patent estate covering all DARPin® applications. About DARPins® DARPins® are a new generation of target-binding proteins which can be isolated from large libraries. The DARPin® platform is an efficient product generating engine creating differentiated and high quality drugs at unmatched speed. Each drug candidate profits from a wide range of beneficial biophysical properties, including high stability and solubility, high yield and low-cost microbial production. Also, DARPins®show very high potencies and pharmacokinetic (PK) profiles tailored to the demand of the application, ranging from minutes to weeks. DARPins® can be effortlessly combined into multispecific drug candidates without compromising biophysical and development characteristics. This rapid and robust generation of multispecific DARPins® allows new combinatorial approaches in exploring target biology. *

	Start	2004-01-01 splitoff
	Industry	pharmaceutical active protein

	Street	14 Wagistr. Bio-Technopark
	City	8952 Schlieren ZH
	Tel	+41-44-755-7700
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2021-03-31)
	Currency	CHF
	Annual sales	9,344,000 (revenues, total, consolidated (2020) 2020-12-31)
	Profit	-62,775,000 (2020-12-31)
	Cash	133,721,000 (2020-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10